Biocon’s Board of Directors has approved the unaudited financial results for Q2 2025-26. The board also approved early redemption of 50,000 unlisted, secured, redeemable Non-Convertible Debentures (NCDs) aggregating to ₹500 Crores, subject to approvals by January 31, 2026. Additionally, the company will acquire Compulsorily Convertible Debentures of Biocon Biologics Limited from Edelweiss for ₹300 Crores.
Financial Results Highlights
The Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025 (Q2 2025-26). Key figures from the standalone results include:
- Revenue from operations: ₹5,833 million
- Total income: ₹7,171 million
- Net Profit: ₹709 million
Non-Convertible Debenture Redemption
The board has approved the early full redemption of 50,000 unlisted, secured, rated, redeemable Non-Convertible Debentures (NCDs) with a face value of ₹1,00,000 each, aggregating to ₹500 Crores. The redemption is subject to the receipt of necessary approvals and/or consents on or before January 31, 2026. These NCDs were initially issued on May 19, 2023, on a private placement basis.
Acquisition of Convertible Debentures
Biocon will acquire 1,06,86,044 unlisted, secured, Compulsorily Convertible Debentures (CCDs) of Biocon Biologics Limited (BBL) from ESOF III Investment Fund and EAAA India Alternatives Limited (Edelweiss). The face value of the CCDs is ₹10 each, aggregating to ₹300 Crores. This acquisition is expected to be completed on or before January 30, 2026, subject to necessary approvals.
Commercial Paper Issuance
The company plans to issue Commercial Papers up to an amount not exceeding ₹550 Crores in one or more tranches on a private placement basis.
Source: BSE
